NeuroOne Medical Technologies (NASDAQ:NMTC) Trading 1.1% Higher – Should You Buy?

Shares of NeuroOne Medical Technologies Co. (NASDAQ:NMTC) rose 1.1% during trading on Monday . The stock traded as high as $0.64 and last traded at $0.62. Approximately 73,000 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 183,402 shares. The stock had previously closed at $0.62.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH started coverage on shares of NeuroOne Medical Technologies in a research report on Monday, May 5th. They set a “buy” rating and a $1.45 price objective on the stock.

NeuroOne Medical Technologies Stock Up 1.1%

The stock has a market capitalization of $31.03 million, a price-to-earnings ratio of -2.40 and a beta of 0.65. The company has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.84.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The company had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.27 billion. NeuroOne Medical Technologies had a negative net margin of 82.17% and a negative return on equity of 270.70%.

Insider Buying and Selling at NeuroOne Medical Technologies

In related news, CEO David A. Rosa bought 100,000 shares of the firm’s stock in a transaction on Friday, April 4th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer now owns 1,161,289 shares of the company’s stock, valued at approximately $580,644.50. This trade represents a 9.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Ronald W. Mcclurg purchased 200,000 shares of the business’s stock in a transaction dated Friday, April 4th. The stock was bought at an average price of $0.50 per share, with a total value of $100,000.00. Following the acquisition, the chief financial officer now directly owns 444,117 shares in the company, valued at approximately $222,058.50. This represents a 81.93% increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in NeuroOne Medical Technologies in the 4th quarter valued at approximately $33,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of NeuroOne Medical Technologies during the 1st quarter worth $69,000. Goldman Sachs Group Inc. purchased a new stake in shares of NeuroOne Medical Technologies in the 1st quarter worth about $84,000. Finally, Geode Capital Management LLC boosted its position in shares of NeuroOne Medical Technologies by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 311,659 shares of the company’s stock worth $257,000 after buying an additional 27,804 shares in the last quarter. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.